Publications

Found 14 results
Filters: Author is J.L. Liu  [Clear All Filters]
2012
Z. W. Liu, Liu, J. L., An, Y., Zhang, L., and Wang, Y. M., Association between Ser311Cys polymorphism in the dopamine D2 receptor gene and schizophrenia risk: a meta-analysis in Asian populations, vol. 11, pp. 261-270, 2012.
Andreasen NC, Arndt S, Alliger R, Miller D, et al. (1995). Symptoms of schizophrenia. Methods, meanings, and mechanisms. Arch. Gen. Psychiatry 52: 341-351. http://dx.doi.org/10.1001/archpsyc.1995.03950170015003 PMid:7726714 Arinami T, Itokawa M, Enguchi H, Tagaya H, et al. (1994). Association of dopamine D2 receptor molecular variant with schizophrenia. Lancet 343: 703-704. http://dx.doi.org/10.1016/S0140-6736(94)91581-4 Arinami T, Itokawa M, Aoki J, Shibuya H, et al. (1996). Further association study on dopamine D2 receptor variant S311C in schizophrenia and affective disorders. Am. J. Med. Genet. 67: 133-138. http://dx.doi.org/10.1002/(SICI)1096-8628(19960409)67:2<133::AID-AJMG2>3.0.CO;2-T Chen CH, Chien SH and Hwu HG (1996). No association of dopamine D2 receptor molecular variant Cys311 and schizophrenia in Chinese patients. Am. J. Med. Genet. 67: 418-420. http://dx.doi.org/10.1002/(SICI)1096-8628(19960726)67:4<418::AID-AJMG19>3.0.CO;2-M Fan H, Zhang F, Xu Y, Huang X, et al. (2010). An association study of DRD2 gene polymorphisms with schizophrenia in a Chinese Han population. Neurosci. Lett. 477: 53-56. http://dx.doi.org/10.1016/j.neulet.2009.11.017 PMid:19913597 Fatemi SH and Folsom TD (2009). The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull 35: 528-548. http://dx.doi.org/10.1093/schbul/sbn187 PMid:19223657    PMCid:2669580 Fujiwara Y, Yamaguchi K, Tanaka Y, Tomita H, et al. (1997). Polymorphism of dopamine receptors and transporter genes in neuropsychiatric diseases. Eur. Neurol. 38 (Suppl 1): 6-10. http://dx.doi.org/10.1159/000113436 PMid:9276194 Glatt SJ, Faraone SV and Tsuang MT (2003). Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia. Mol. Psychiatry 8: 911-915. http://dx.doi.org/10.1038/sj.mp.4001321 PMid:14593428 Gupta M, Chauhan C, Bhatnagar P, Gupta S, et al. (2009). Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics 10: 277-291. http://dx.doi.org/10.2217/14622416.10.2.277 PMid:19207030 Harano M (1997). Ser-311-Cys polymorphism of the dopamine D2 receptor gene and schizophrenia - an analysis of schizophrenic patients in Fukuoka. Kurume Med. J. 44: 201-208. http://dx.doi.org/10.2739/kurumemedj.44.201 PMid:9339651 Hattori M, Nanko S, Dai XY, Fukuda R, et al. (1994). Mismatch PCR RFLP detection of DRD2 Ser311Cys polymorphism and schizophrenia. Biochem. Biophys. Res. Commun. 202: 757-763. http://dx.doi.org/10.1006/bbrc.1994.1995 PMid:7914079 Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558. http://dx.doi.org/10.1002/sim.1186 PMid:12111919 Himei A, Koh J, Sakai J, Inada Y, et al. (2002). The influence on the schizophrenic symptoms by the DRD2Ser/Cys311 and -141C Ins/Del polymorphisms. Psychiatry Clin. Neurosci. 56: 97-102. http://dx.doi.org/10.1046/j.1440-1819.2002.00935.x PMid:11929577 Hori H, Ohmori O, Shinkai T, Kojima H, et al. (2001). Association analysis between two functional dopamine D2 receptor gene polymorphisms and schizophrenia. Am. J. Med. Genet. 105: 176-178. http://dx.doi.org/10.1002/ajmg.1196 PMid:11304833 Itokawa M, Arinami T, Futamura N, Hamaguchi H, et al. (1993). A structural polymorphism of human dopamine D2 receptor, D2(Ser311→Cys). Biochem. Biophys. Res. Commun. 196: 1369-1375. http://dx.doi.org/10.1006/bbrc.1993.2404 PMid:7902708 Jönsson EG, Sillen A, Vares M, Ekholm B, et al. (2003). Dopamine D2 receptor gene Ser311Cys variant and schizophrenia: association study and meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 119B: 28-34. http://dx.doi.org/10.1002/ajmg.b.20004 PMid:12707934 Kaneshima M, Higa T, Nakamoto H and Nagamine M (1997). An association study between the Cys311 variant of dopamine D2 receptor gene and schizophrenia in the Okinawan population. Psychiatry Clin. Neurosci. 51: 379-381. http://dx.doi.org/10.1111/j.1440-1819.1997.tb02603.x PMid:9472122 McGrath J, Saha S, Chant D and Welham J (2008). Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30: 67-76. http://dx.doi.org/10.1093/epirev/mxn001 PMid:18480098 Morimoto K, Miyatake R, Nakamura M, Watanabe T, et al. (2002). Delusional disorder: molecular genetic evidence for dopamine psychosis. Neuropsychopharmacology 26: 794-801. http://dx.doi.org/10.1016/S0893-133X(01)00421-3 Nanko S, Hattori M, Dai XY, Fukuda R, et al. (1994). DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343: 1044. http://dx.doi.org/10.1016/S0140-6736(94)90167-8 Ohara K, Nakamura Y, Xie DW, Ishigaki T, et al. (1996). Polymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophrenia. Biol. Psychiatry 40: 1209-1217. http://dx.doi.org/10.1016/0006-3223(95)00673-7 Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. http://dx.doi.org/10.1001/jama.295.6.676 PMid:16467236 Sawa A and Snyder SH (2002). Schizophrenia: diverse approaches to a complex disease. Science 296: 692-695. http://dx.doi.org/10.1126/science.1070532 PMid:11976442 Seeman P (2010). Dopamine D2 receptors as treatment targets in schizophrenia. Clin. Schizophr. Relat. Psychoses 4: 56-73. http://dx.doi.org/10.3371/CSRP.4.1.5 Tanaka T, Igarashi S, Onodera O, Tanaka H, et al. (1996). Lack of association between dopamine D2 receptor gene Cys311 variant and schizophrenia. Am. J. Med. Genet. 67: 208-211. http://dx.doi.org/10.1002/(SICI)1096-8628(19960409)67:2<208::AID-AJMG12>3.0.CO;2-N Viechtbauer W (2007). Confidence intervals for the amount of heterogeneity in meta-analysis. Stat. Med. 26: 37-52. http://dx.doi.org/10.1002/sim.2514 PMid:16463355 Zhang Y, Bertolino A, Fazio L, Blasi G, et al. (2007). Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc. Natl. Acad. Sci. U. S. A. 104: 20552- 20557. http://dx.doi.org/10.1073/pnas.0707106104 PMid:18077373    PMCid:2154469 Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137. http://dx.doi.org/10.1002/gepi.20048 PMid:15593093
2011
D. Wu, Wu, Y., Liu, J. L., Wang, B., and Zhang, X. D., Association between HLA-Cw*0602 polymorphism and psoriasis risk: a meta-analysis, vol. 10, pp. 3109-3120, 2011.
Asumalahti K, Laitinen T, Itkonen-Vatjus R, Lokki ML, et al. (2000). A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum. Mol. Genet. 9: 1533-1542. http://dx.doi.org/10.1093/hmg/9.10.1533 PMid:10888604 Attia J, Thakkinstian A and D’Este C (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J. Clin. Epidemiol. 56: 297-303. http://dx.doi.org/10.1016/S0895-4356(03)00011-8 Brandrup F, Holm N, Grunnet N, Henningsen K, et al. (1982). Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm. Venereol. 62: 229-236. PMid:6179364 Brazzelli V, Quaglini M, Martinetti M, Nolli G, et al. (2000). A peculiar sequence motif in the alpha-1-domain of the HLA-C molecule in psoriasis. Dermatology 200: 99-103. http://dx.doi.org/10.1159/000018338 PMid:10773694 Chandran V and Raychaudhuri SP (2010). Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J. Autoimmun. 34: J314-J321. http://dx.doi.org/10.1016/j.jaut.2009.12.001 PMid:20034760 Chang YT, Shiao YM, Chin PJ, Liu YL, et al. (2004). Genetic polymorphisms of the HCR gene and a genomic segment in close proximity to HLA-C are associated with patients with psoriasis in Taiwan. Br. J. Dermatol. 150: 1104-1111. http://dx.doi.org/10.1111/j.1365-2133.2004.05972.x PMid:15214895 Chang YT, Liu HN, Shiao YM, Lin MW, et al. (2005). A study of PSORS1C1 gene polymorphisms in Chinese patients with psoriasis. Br. J. Dermatol. 153: 90-96. http://dx.doi.org/10.1111/j.1365-2133.2005.06570.x PMid:16029332 Chang YT, Chou CT, Shiao YM, Lin MW, et al. (2006). Psoriasis vulgaris in Chinese individuals is associated with PSORS1C3 and CDSN genes. Br. J. Dermatol. 155: 663-669. http://dx.doi.org/10.1111/j.1365-2133.2006.07420.x PMid:16965413 Duffin KC, Chandran V, Gladman DD, Krueger GG, et al. (2008). Genetics of psoriasis and psoriatic arthritis: update and future direction. J. Rheumatol. 35: 1449-1453. PMid:18609743    PMCid:2724000 Fan X, Yang S, Sun LD, Liang YH, et al. (2007). Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm. Venereol. 87: 335-340. http://dx.doi.org/10.2340/00015555-0253 PMid:17598037 Farber EM, Nall ML and Watson W (1974). Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 109: 207-211. http://dx.doi.org/10.1001/archderm.1974.01630020023005 PMid:4814926 Fojtíková M, Stolfa J, Novota P, Cejkova P, et al. (2009). HLA-Cw*06 class I region rather than MICA is associated with psoriatic arthritis in Czech population. Rheumatol. Int. 29: 1293-1299. http://dx.doi.org/10.1007/s00296-009-0847-1 PMid:19184033 Gonzalez S, Martinez-Borra J, Torre-Alonso JC, Gonzalez-Roces S, et al. (1999). The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum. 42: 1010-1016. http://dx.doi.org/10.1002/1529-0131(199905)42:5<1010::AID-ANR21>3.0.CO;2-H Griffiths CE and Barker JN (2007). Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271. http://dx.doi.org/10.1016/S0140-6736(07)61128-3 Gudjonsson JE, Karason A, Antonsdottir A, Runarsdottir EH, et al. (2003). Psoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotes. Br. J. Dermatol. 148: 233-235. http://dx.doi.org/10.1046/j.1365-2133.2003.05115.x PMid:12588373 Gudjonsson JE, Johnston A, Sigmundsdottir H and Valdimarsson H (2004). Immunopathogenic mechanisms in psoriasis. Clin. Exp. Immunol. 135: 1-8. http://dx.doi.org/10.1111/j.1365-2249.2004.02310.x PMid:14678257    PMCid:1808928 Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558. http://dx.doi.org/10.1002/sim.1186 PMid:12111919 Holm SJ, Sanchez F, Carlen LM, Mallbris L, et al. (2005a). HLA-Cw*0602 associates more strongly to psoriasis in the Swedish population than variants of the novel 6p21.3 gene PSORS1C3. Acta Derm. Venereol. 85: 2-8. http://dx.doi.org/10.1080/00015550410023527 Holm SJ, Sakuraba K, Mallbris L, Wolk K, et al. (2005b). Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J. Invest. Dermatol. 125: 721-730. http://dx.doi.org/10.1111/j.0022-202X.2005.23879.x PMid:16185272 Jobim M, Jobim LF, Salim PH, Cestari TF, et al. (2008). A study of the killer cell immunoglobulin-like receptor gene KIR2DS1 in a Caucasoid Brazilian population with Psoriasis vulgaris. Tissue Antigens 72: 392-396. http://dx.doi.org/10.1111/j.1399-0039.2008.01096.x PMid:18643961 Liu Y, Helms C, Liao W, Zaba LC, et al. (2008). A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 4: e1000041. http://dx.doi.org/10.1371/journal.pgen.1000041 PMid:18369459    PMCid:2274885 Lowes MA, Bowcock AM and Krueger JG (2007). Pathogenesis and therapy of psoriasis. Nature 445: 866-873. http://dx.doi.org/10.1038/nature05663 PMid:17314973 Luft FC (2005). Light shed on the common skin scourge, psoriasis. J. Mol. Med. 83: 933-934. http://dx.doi.org/10.1007/s00109-005-0724-7 PMid:16323032 Luszczek W, Kubicka W, Cislo M, Nockowski P, et al. (2003). Strong association of HLA-Cw6 allele with juvenile psoriasis in Polish patients. Immunol. Lett. 85: 59-64. http://dx.doi.org/10.1016/S0165-2478(02)00212-2 Mallbris L, Wolk K, Sanchez F and Stahle M (2009). HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis: a case control study. BMC Dermatol. 9: 5. http://dx.doi.org/10.1186/1471-5945-9-5 PMid:19480679    PMCid:2696405 Martínez-Borra J, Gonzalez S, Santos-Juanes J, Sanchez del RJ, et al. (2003). Psoriasis vulgaris and psoriatic arthritis share a 100 kb susceptibility region telomeric to HLA-C. Rheumatology 42: 1089-1092. http://dx.doi.org/10.1093/rheumatology/keg304 PMid:12730526 Martínez-Borra J, Brautbar C, Gonzalez S, Enk CD, et al. (2005). The region of 150 kb telometic to HLA-C is associated with psoriasis in the Jewish population. J. Invest. Dermatol. 125: 928-932. PMid:16297191 Nair RP, Stuart PE, Nistor I, Hiremagalore R, et al. (2006). Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am. J. Hum. Genet. 78: 827-851. http://dx.doi.org/10.1086/503821 PMid:16642438 Naldi L and Mercuri SR (2010). Epidemiology of comorbidities in psoriasis. Dermatol. Ther. 23: 114-118. http://dx.doi.org/10.1111/j.1529-8019.2010.01304.x PMid:20415817 Nestle FO, Kaplan DH and Barker J (2009). Psoriasis. N. Engl. J. Med. 361: 496-509. http://dx.doi.org/10.1056/NEJMra0804595 PMid:19641206 Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. http://dx.doi.org/10.1001/jama.295.6.676 PMid:16467236 Płoski R, Luszczek W, Kuśnierczyk P, Nockowski P, et al. (2006). A role for KIR gene variants other than KIR2DS1 in conferring susceptibility to psoriasis. Hum. Immunol. 67: 521-526. http://dx.doi.org/10.1016/j.humimm.2006.04.001 PMid:16829306 Rani R, Narayan R, Fernandez-Vina MA and Stastny P (1998). Role of HLA-B and C alleles in development of psoriasis in patients from North India. Tissue Antigens 51: 618-622. http://dx.doi.org/10.1111/j.1399-0039.1998.tb03004.x PMid:9694354 Raychaudhuri SP and Gross J (2000a). A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr. Dermatol. 17: 174-178. http://dx.doi.org/10.1046/j.1525-1470.2000.01746.x PMid:10886746 Raychaudhuri SP and Gross J (2000b). Psoriasis risk factors: role of lifestyle practices. Cutis 66: 348-352. PMid:11107520 Raychaudhuri SP and Farber EM (2001). The prevalence of psoriasis in the world. J. Eur. Acad. Dermatol. Venereol. 15: 16-17. http://dx.doi.org/10.1046/j.1468-3083.2001.00192.x PMid:11451313 Reveille JD and Williams FM (2006). Infection and musculoskeletal conditions: Rheumatologic complications of HIV infection. Best Pract. Res. Clin. Rheumatol. 20: 1159-1179. http://dx.doi.org/10.1016/j.berh.2006.08.015 Sánchez F, Holm SJ, Mallbris L, O’Brien KP, et al. (2004). STG does not associate with psoriasis in the Swedish population. Exp. Dermatol. 13: 413-418. http://dx.doi.org/10.1111/j.0906-6705.2004.00170.x PMid:15217361 Schon MP and Boehncke WH (2005). Psoriasis. N. Engl. J. Med. 352: 1899-1912. http://dx.doi.org/10.1056/NEJMra041320 PMid:15872205 Szczerkowska-Dobosz A (2005). Human leukocyte antigens as psoriasis inheritance and susceptibility markers. Arch. Immunol. Ther. Exp. 53: 428-433. Valdimarsson H (2007). The genetic basis of psoriasis. Clin. Dermatol. 25: 563-567. http://dx.doi.org/10.1016/j.clindermatol.2007.08.010 PMid:18021893 Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, et al. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835. http://dx.doi.org/10.1097/EDE.0b013e3181577511 PMid:18049195 Watson W, Cann HM, Farber EM and Nall ML (1972). The genetics of psoriasis. Arch. Dermatol. 105: 197-207. http://dx.doi.org/10.1001/archderm.1972.01620050011002 PMid:5060862 Zhang XJ, Zhang AP, Yang S, Gao M, et al. (2003). Association of HLA class I alleles with Psoriasis vulgaris in southeastern Chinese Hans. J. Dermatol. Sci. 33: 1-6. http://dx.doi.org/10.1016/S0923-1811(03)00157-9 Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137. http://dx.doi.org/10.1002/gepi.20048 PMid:15593093
Y. Wu, Wang, B., Liu, J. L., Gao, X. H., Chen, H. D., and Li, Y. H., Association of -619C/T polymorphism in CDSN gene and psoriasis risk: a meta-analysis, vol. 10, pp. 3632-3640, 2011.
Ahnini RT, Camp NJ, Cork MJ, Mee JB, et al. (1999). Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Hum. Mol. Genet. 8: 1135-1140. http://dx.doi.org/10.1093/hmg/8.6.1135   Ameen M, Allen MH, Fisher SA, Lewis CM, et al. (2005). Corneodesmosin (CDSN) gene association with psoriasis vulgaris in Caucasian but not in Japanese populations. Clin. Exp. Dermatol. 30: 414-418. http://dx.doi.org/10.1111/j.1365-2230.2005.01789.x PMid:15953084   Asumalahti K, Laitinen T, Itkonen-Vatjus R, Lokki ML, et al. (2000). A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum. Mol. Genet. 9: 1533-1542. http://dx.doi.org/10.1093/hmg/9.10.1533 PMid:10888604   Attia J, Thakkinstian A and D'Este C (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J. Clin. Epidemiol. 56: 297-303. http://dx.doi.org/10.1016/S0895-4356(03)00011-8   Genetics and Molecular Research 10 (4): 3632-3640 (2011) Butt C, Rahman P, Siannis F, Farewell VT, et al. (2005). Corneodesmosin polymorphisms in psoriatic arthritis. Rheumatology 44: 684-685.   Capon F, Munro M, Barker J and Trembath R (2002). Searching for the major histocompatibility complex psoriasis susceptibility gene. J. Invest. Dermatol. 118: 745-751. http://dx.doi.org/10.1046/j.1523-1747.2002.01749.x PMid:11982750   Capon F, Toal IK, Evans JC, Allen MH, et al. (2003). Haplotype analysis of distantly related populations implicates corneodesmosin in psoriasis susceptibility. J. Med. Genet. 40: 447-452. http://dx.doi.org/10.1136/jmg.40.6.447 PMid:12807967 PMCid:1735499   Caubet C, Jonca N, Brattsand M, Guerrin M, et al. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 122: 1235-1244. http://dx.doi.org/10.1111/j.0022-202X.2004.22512.x PMid:15140227   Chang YT, Tsai SF, Lin MW, Liu HN, et al. (2003). SPR1 gene near HLA-C is unlikely to be a psoriasis susceptibility gene. Exp. Dermatol. 12: 307-314. http://dx.doi.org/10.1034/j.1600-0625.2003.00039.x PMid:12823445   Chang YT, Chou CT, Shiao YM, Lin MW, et al. (2006). Psoriasis vulgaris in Chinese individuals is associated with PSORS1C3 and CDSN genes. Br. J. Dermatol. 155: 663-669. http://dx.doi.org/10.1111/j.1365-2133.2006.07420.x PMid:16965413   Griffiths CE and Barker JN (2007). Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271. http://dx.doi.org/10.1016/S0140-6736(07)61128-3   Guerrin M, Simon M, Montezin M, Haftek M, et al. (1998). Expression cloning of human corneodesmosin proves its identity with the product of the S gene and allows improved characterization of its processing during keratinocyte differentiation. J. Biol. Chem. 273: 22640-22647. http://dx.doi.org/10.1074/jbc.273.35.22640 PMid:9712893   Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558. http://dx.doi.org/10.1002/sim.1186 PMid:12111919   Hui J, Oka A, Tamiya G, Tomizawa M, et al. (2002). Corneodesmosin DNA polymorphisms in MHC haplotypes and Japanese patients with psoriasis. Tissue Antigens 60: 77-83. http://dx.doi.org/10.1034/j.1399-0039.2002.600110.x PMid:12366786   Krueger JG, Krane JF, Carter DM and Gottlieb AB (1990). Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J. Invest. Dermatol. 94: 135S-140S. http://dx.doi.org/10.1111/1523-1747.ep12876121 PMid:2161887   Liu Y, Krueger JG and Bowcock AM (2007). Psoriasis: genetic associations and immune system changes. Genes Immun. 8: 1-12. http://dx.doi.org/10.1038/sj.gene.6364351 PMid:17093502   O'Brien KP, Holm SJ, Nilsson S, Carlen L, et al. (2001). The HCR gene on 6p21 is unlikely to be a psoriasis susceptibility gene. J. Invest. Dermatol. 116: 750-754. http://dx.doi.org/10.1046/j.0022-202x.2001.01323.x PMid:11348465   Orrù S, Giuressi E, Casula M, Loizedda A, et al. (2002). Psoriasis is associated with a SNP haplotype of the corneodesmosin gene (CDSN). Tissue Antigens 60: 292-298. http://dx.doi.org/10.1034/j.1399-0039.2002.600403.x PMid:12472658   Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in metaanalysis. JAMA 295: 676-680. http://dx.doi.org/10.1001/jama.295.6.676 PMid:16467236   Romphruk AV, Oka A, Romphruk A, Tomizawa M, et al. (2003). Corneodesmosin gene: no evidence for PSORS 1 gene in North-eastern Thai psoriasis patients. Tissue Antigens 62: 217-224. http://dx.doi.org/10.1034/j.1399-0039.2003.00056.x PMid:12956875   Schmitt-Egenolf M, Windemuth C, Hennies HC, Albis-Camps M, et al. (2001). Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families. Tissue Antigens 57: 440-446. http://dx.doi.org/10.1034/j.1399-0039.2001.057005440.x PMid:11556968   Terui T, Ozawa M and Tagami H (2000). Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: a neutrophil-associated inflammation-boosting loop. Exp. Dermatol. 9: 1-10. http://dx.doi.org/10.1034/j.1600-0625.2000.009001001.x PMid:10688368   Vandenbroucke JP, von EE, Altman DG, Gotzsche PC, et al. (2007). Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835. http://dx.doi.org/10.1097/EDE.0b013e3181577511 PMid:18049195   Zenz R, Eferl R, Kenner L, Florin L, et al. (2005). Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437: 369-375. http://dx.doi.org/10.1038/nature03963 PMid:16163348   Zintzaras E and Loannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137. http://dx.doi.org/10.1002/gepi.20048 PMid:15593093
D. Chen, Liu, J. L., Liu, Y., Zhu, J., and Wang, S. W., Lack of an association between -308G>A polymorphism of the TNF-α gene and liver cirrhosis risk based on a meta-analysis, vol. 10, pp. 2765-2774, 2011.
Bahr MJ, el Menuawy M, Boeker KH, Musholt PB, et al. (2003). Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int. 23: 420-425. http://dx.doi.org/10.1111/j.1478-3231.2003.00873.x PMid:14986816 Bataller R, North KE and Brenner DA (2003). Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37: 493-503. http://dx.doi.org/10.1053/jhep.2003.50127 PMid:12601343 Cha C and Dematteo RP (2005). Molecular mechanisms in hepatocellular carcinoma development. Best Pract. Res. Clin. Gastroenterol. 19: 25-37. http://dx.doi.org/10.1016/j.bpg.2004.11.005 Chan HL, Tse AM, Chim AM, Wong VW, et al. (2008). Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. J. Gastroenterol. Hepatol. 23: 783-789. http://dx.doi.org/10.1111/j.1440-1746.2007.05110.x PMid:17645476 Chen YQ, Lin JS, Tian DY and Liang KH (2003). Study on the association between the promoter polymorphism of TNF gene and cirrhosis. World J. Infect. 3: 186-190. Choi J and Ou JH (2006). Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G847-G851. http://dx.doi.org/10.1152/ajpgi.00522.2005 PMid:16603728 Chuang E, Del Vecchio A, Smolinski S, Song XY, et al. (2004). Biomedicines to reduce inflammation but not viral load in chronic HCV-what’s the sense? Trends Biotechnol. 22: 517-523. http://dx.doi.org/10.1016/j.tibtech.2004.08.011 PMid:15450745 Commins SP, Borish L and Steinke JW (2010). Immunologic messenger molecules: cytokines, interferons, and chemokines. J. Allergy Clin. Immunol. 125: S53-S72. http://dx.doi.org/10.1016/j.jaci.2009.07.008 PMid:19932918 Constantini PK, Wawrzynowicz-Syczewska M, Clare M, Boron-Kaczmarska A, et al. (2002). Interleukin-1, interleukin-10 and tumour necrosis factor-alpha gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to alpha-interferon therapy. Liver 22: 404-412. http://dx.doi.org/10.1034/j.1600-0676.2002.01553.x Cua IH, Hui JM, Bandara P, Kench JG, et al. (2007). Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology 46: 66-73. http://dx.doi.org/10.1002/hep.21703 PMid:17596870 Cuenca J, Perez CA, Aguirre AJ, Schiattino I, et al. (2001). Genetic polymorphism at position-308 in the promoter region of the tumor necrosis factor (TNF): implications of its allelic distribution on susceptibility or resistance to diseases in the Chilean population. Biol. Res. 34: 237-241. http://dx.doi.org/10.4067/S0716-97602001000300011 PMid:11715861 Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, et al. (2005). Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr. Med. Res. Opin. 21: 527-534. http://dx.doi.org/10.1185/030079905X38141 PMid:15899101 Falasca K, Ucciferri C, Dalessandro M, Zingariello P, et al. (2006). Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 36: 144-150. PMid:16682509 Fan LY, Zhong RQ, Tu XQ, Pfeiffer T, et al. (2004). Genetic association of tumor necrosis factor (TNF)-alpha polymorphisms with primary biliary cirrhosis and autoimmune liver diseases in a Chinese population. Zhonghua Gan Zang Bing Za Zhi 12: 160-162. PMid:15059302 Friedman SL (2010). Evolving challenges in hepatic fibrosis. Nat. Rev. Gastroenterol. Hepatol. 7: 425-436. http://dx.doi.org/10.1038/nrgastro.2010.97 Gordon MA, Oppenheim E, Camp NJ, di Giovine FS, et al. (1999). Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region. J. Hepatol. 31: 242-247. http://dx.doi.org/10.1016/S0168-8278(99)80220-7 Hajeer AH and Hutchinson IV (2000). TNF-alpha gene polymorphism: clinical and biological implications. Microsc. Res. Tech. 50: 216-228. http://dx.doi.org/10.1002/1097-0029(20000801)50:3<216::AID-JEMT5>3.0.CO;2-Q Hajeer AH and Hutchinson IV (2001). Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum. Immunol. 62: 1191-1199. http://dx.doi.org/10.1016/S0198-8859(01)00322-6 Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558. http://dx.doi.org/10.1002/sim.1186 PMid:12111919 Jeng JE, Tsai JF, Chuang LY, Ho MS, et al. (2007). Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 9: 987-992. http://dx.doi.org/10.1593/neo.07781 PMid:18030367 Jiang ZL, Zhang W, Zhang H and Liu YB (2009). Relationship between TNF-alpha, TGF-beta1 and IL-10 genetic polymorphisms and post- hepatitis B cirrhosis. Shi Jie Hua Ren Xiao Hua 17: 3263-3268. Jones DE, Watt FE, Grove J, Newton JL, et al. (1999). Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. J. Hepatol. 30: 232-236. http://dx.doi.org/10.1016/S0168-8278(99)80067-1 Juran BD, Atkinson EJ, Larson JJ, Schlicht EM, et al. (2010). Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction. Hepatology 52: 223-229. http://dx.doi.org/10.1002/hep.23667 PMid:20578265    PMCid:2922843 Kamal SM, Turner B, He Q, Rasenack J, et al. (2006). Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 43: 771-779. http://dx.doi.org/10.1002/hep.21117 PMid:16557547 Li Y, Chang M, Abar O, Garcia V, et al. (2009). Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J. Hepatol. 51: 750-757. http://dx.doi.org/10.1016/j.jhep.2009.04.027 PMid:19586676    PMCid:2883297 Lim YS and Kim WR (2008). The global impact of hepatic fibrosis and end-stage liver disease. Clin. Liver Dis. 12: 733- 46, vii. http://dx.doi.org/10.1016/j.cld.2008.07.007 PMid:18984463 Mallat A, Hezode C and Lotersztajn S (2008). Environmental factors as disease accelerators during chronic hepatitis C. J. Hepatol. 48: 657-665. http://dx.doi.org/10.1016/j.jhep.2008.01.004 PMid:18279998 Nguyen-Khac E, Houchi H, Daoust M, Dupas JL, et al. (2008). The -308 TNFalpha gene polymorphism in severe acute alcoholic hepatitis: identification of a new susceptibility marker. Alcohol. Clin. Exp. Res. 32: 822-828. http://dx.doi.org/10.1111/j.1530-0277.2008.00629.x PMid:18336639 Niro GA, Poli F, Andriulli A, Bianchi I, et al. (2009). TNF-alpha polymorphisms in primary biliary cirrhosis: a northern and southern Italian experience. Ann. N. Y. Acad. Sci. 1173: 557-563. http://dx.doi.org/10.1111/j.1749-6632.2009.04741.x PMid:19758199 Oo YH, Hubscher SG and Adams DH (2010). Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol. Int. 4: 475-493. http://dx.doi.org/10.1007/s12072-010-9183-5 PMid:20827405    PMCid:2900560 Pastor IJ, Laso FJ, Romero A and Gonzalez-Sarmiento R (2005). -238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. Alcohol. Clin. Exp. Res. 29: 1928-1931. http://dx.doi.org/10.1097/01.alc.0000187595.19324.ca Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. http://dx.doi.org/10.1001/jama.295.6.676 PMid:16467236 Poynard T, Mathurin P, Lai CL, Guyader D, et al. (2003). A comparison of fibrosis progression in chronic liver diseases. J. Hepatol. 38: 257-265. http://dx.doi.org/10.1016/S0168-8278(02)00413-0 Schwabe RF and Brenner DA (2006). Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G583-G589. http://dx.doi.org/10.1152/ajpgi.00422.2005 PMid:16537970 Tahara T, Shibata T, Nakamura M, Yamashita H, et al. (2009). Effect of polymorphisms in the 3’ untranslated region (3’- UTR) of vascular endothelial growth factor gene on gastric cancer and peptic ulcer diseases in Japan. Mol. Carcinog. 48: 1030-1037. http://dx.doi.org/10.1002/mc.20554 PMid:19496079 Tanaka A, Quaranta S, Mattalia A, Coppel R, et al. (1999). The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J. Hepatol. 30: 826-829. http://dx.doi.org/10.1016/S0168-8278(99)80135-4 Thimme R, Wieland S, Steiger C, Ghrayeb J, et al. (2003). CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77: 68-76. http://dx.doi.org/10.1128/JVI.77.1.68-76.2003 PMid:12477811    PMCid:140637 Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, et al. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835. http://dx.doi.org/10.1097/EDE.0b013e3181577511 PMid:18049195 Wilson AG, di Giovine FS, Blakemore AI and Duff GW (1992). Single base polymorphism in the human tumour necrosis factor alpha (TNF-alpha) gene detectable by NcoI restriction of PCR product. Hum. Mol. Genet. 1: 353. http://dx.doi.org/10.1093/hmg/1.5.353 PMid:1363876 Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137. http://dx.doi.org/10.1002/gepi.20048 PMid:15593093
M. S. Li, Liu, J. L., Wu, Y., Wang, P., and Teng, H., Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk, vol. 10, pp. 2924-2933, 2011.
Coughlin SS and Hall IJ (2002). A review of genetic polymorphisms and prostate cancer risk. Ann. Epidemiol. 12: 182- 196. http://dx.doi.org/10.1016/S1047-2797(01)00310-6 Guimaraes DP and Hainaut P (2002). TP53: a key gene in human cancer. Biochimie 84: 83-93. http://dx.doi.org/10.1016/S0300-9084(01)01356-6 Henner WD, Evans AJ, Hough KM, Harris EL, et al. (2001). Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 49: 263-266. http://dx.doi.org/10.1002/pros.10021 PMid:11746272 Higgins JP and Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat. Med. 21: 1539-1558. http://dx.doi.org/10.1002/sim.1186 PMid:12111919 Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991). p53 mutations in human cancers. Science 253: 49-53. http://dx.doi.org/10.1126/science.1905840 PMid:1905840 Hsing AW and Chokkalingam AP (2006). Prostate cancer epidemiology. Front. Biosci. 11: 1388-1413. http://dx.doi.org/10.2741/1891 PMid:16368524 Huang SP, Wu WJ, Chang WS, Wu MT, et al. (2004). p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Canc. Epidemiol. Biomarkers Prev. 13: 2217-2224. PMid:15598783 Jemal A, Siegel R, Xu J and Ward E (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60: 277-300. http://dx.doi.org/10.3322/caac.20073 PMid:20610543 Katkoori VR, Jia X, Shanmugam C, Wan W, et al. (2009). Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin. Cancer Res. 15: 2406-2416. http://dx.doi.org/10.1158/1078-0432.CCR-08-1719 PMid:19339276 Klug SJ, Ressing M, Koenig J, Abba MC, et al. (2009). TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 10: 772-784. http://dx.doi.org/10.1016/S1470-2045(09)70187-1 Leiros GJ, Galliano SR, Sember ME, Kahn T, et al. (2005). Detection of human papillomavirus DNA and p53 codon 72 polymorphism in prostate carcinomas of patients from Argentina. BMC Urol. 5: 15. http://dx.doi.org/10.1186/1471-2490-5-15 PMid:16307686 PMCid:1314892 Lesko SM, Rosenberg L and Shapiro S (1996). Family history and prostate cancer risk. Am. J. Epidemiol. 144: 1041-1047. PMid:8942435 Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331. http://dx.doi.org/10.1016/S0092-8674(00)81871-1 Levine AJ, Momand J and Finlay CA (1991). The p53 tumour suppressor gene. Nature 351: 453-456. http://dx.doi.org/10.1038/351453a0 PMid:2046748 Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, et al. (2000). Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343: 78-85. http://dx.doi.org/10.1056/NEJM200007133430201 PMid:10891514 Mechanic LE, Bowman ED, Welsh JA, Khan MA, et al. (2007). Common genetic variation in TP53 is associated with lung cancer risk and prognosis in African Americans and somatic mutations in lung tumors. Cancer Epidemiol. Biomarkers Prev. 16: 214-222. http://dx.doi.org/10.1158/1055-9965.EPI-06-0790 Pegoraro RJ, Moodley M, Rom L, Chetty R, et al. (2003). P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int. J. Gynecol. Cancer 13: 444-449. http://dx.doi.org/10.1046/j.1525-1438.2003.13333.x PMid:12911720 Peters JL, Sutton AJ, Jones DR, Abrams KR, et al. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680. http://dx.doi.org/10.1001/jama.295.6.676 PMid:16467236 Quinones LA, Irarrazabal CE, Rojas CR, Orellana CE, et al. (2006). Joint effect among p53, CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: an exploratory genotype-environment interaction study. Asian J. Androl. 8: 349-355. http://dx.doi.org/10.1111/j.1745-7262.2006.00135.x PMid:16625286 Ricks-Santi L, Mason T, Apprey V, Ahaghotu C, et al. (2010). p53 Pro72Arg polymorphism and prostate cancer in men of African descent. Prostate 70: 1739-1745. PMid:20593380 PMCid:3057117 Shepherd T, Tolbert D, Benedetti J, Macdonald J, et al. (2000). Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 118: 1039-1044. http://dx.doi.org/10.1016/S0016-5085(00)70356-8 Suzuki K, Matsui H, Ohtake N, Nakata S, et al. (2003). A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J. Biomed. Sci. 10: 430-435. http://dx.doi.org/10.1007/BF02256434 PMid:12824702 Tsai MH, Lin CD, Hsieh YY, Chang FC, et al. (2002). Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112: 116-119. http://dx.doi.org/10.1097/00005537-200201000-00020 PMid:11802048 Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, et al. (2007). STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 18: 805-835. http://dx.doi.org/10.1097/EDE.0b013e3181577511 PMid:18049195 Viechtbauer W (2007). Confidence intervals for the amount of heterogeneity in meta-analysis. Stat. Med. 26: 37-52. http://dx.doi.org/10.1002/sim.2514 PMid:16463355 Wang YC, Chen CY, Chen SK, Chang YY, et al. (1999). p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin. Cancer Res. 5: 129-134. PMid:9918210 Wu HC, Chang CH, Chen HY, Tsai FJ, et al. (2004). p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol. Int. 73: 41-46. http://dx.doi.org/10.1159/000078803 PMid:15263792 Wu WJ, Kakehi Y, Habuchi T, Kinoshita H, et al. (1995). Allelic frequency of p53 gene codon 72 polymorphism in urologic cancers. Jpn. J. Cancer Res. 86: 730-736. http://dx.doi.org/10.1111/j.1349-7006.1995.tb02461.x Zhou Y, Li N, Zhuang W, Liu GJ, et al. (2007). P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer 121: 1481-1486. http://dx.doi.org/10.1002/ijc.22833 PMid:17546594 Zintzaras E and Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28: 123-137. http://dx.doi.org/10.1002/gepi.20048 PMid:15593093